Eli Lilly's orforglipron achieves key trial success, advancing obesity and diabetes treatment
Eli Lilly's oral GLP-1 receptor agonist, orforglipron, successfully met primary and secondary endpoints in a Phase 3 trial, showing significant weight loss and A1C reduction in adults with obesity or overweight and type 2 diabetes, leading to plans for global regulatory submissions.